These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 37463038)

  • 1. Discovery of the First Irreversible HDAC6 Isoform Selective Inhibitor with Potent Anti-Multiple Myeloma Activity.
    Liu F; Liu C; Chai Q; Zhao C; Meng H; Xue X; Yao TP; Zhang Y
    J Med Chem; 2023 Jul; 66(14):10080-10091. PubMed ID: 37463038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
    Senger J; Melesina J; Marek M; Romier C; Oehme I; Witt O; Sippl W; Jung M
    J Med Chem; 2016 Feb; 59(4):1545-55. PubMed ID: 26653328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
    Negmeldin AT; Pflum MKH
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors.
    Porter NJ; Mahendran A; Breslow R; Christianson DW
    Proc Natl Acad Sci U S A; 2017 Dec; 114(51):13459-13464. PubMed ID: 29203661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selectivity of Hydroxamate- and Difluoromethyloxadiazole-Based Inhibitors of Histone Deacetylase 6 In Vitro and in Cells.
    Ptacek J; Snajdr I; Schimer J; Kutil Z; Mikesova J; Baranova P; Havlinova B; Tueckmantel W; Majer P; Kozikowski A; Barinka C
    Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological evaluation of HDAC6 inhibitors targeting L1 loop and serine 531 residue.
    Jha S; Kim JH; Kim M; Nguyen AH; Ali KH; Gupta SK; Park SY; Ha E; Seo YH
    Eur J Med Chem; 2024 Feb; 265():116057. PubMed ID: 38142511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
    Tavares MT; de Almeida LC; Kronenberger T; Monteiro Ferreira G; Fujii de Divitiis T; Franco Zannini Junqueira Toledo M; Mariko Aymoto Hassimotto N; Agostinho Machado-Neto J; Veras Costa-Lotufo L; Parise-Filho R
    Bioorg Med Chem; 2021 Apr; 35():116085. PubMed ID: 33668008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors.
    Smil DV; Manku S; Chantigny YA; Leit S; Wahhab A; Yan TP; Fournel M; Maroun C; Li Z; Lemieux AM; Nicolescu A; Rahil J; Lefebvre S; Panetta A; Besterman JM; Déziel R
    Bioorg Med Chem Lett; 2009 Feb; 19(3):688-92. PubMed ID: 19111466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability.
    Jochems J; Boulden J; Lee BG; Blendy JA; Jarpe M; Mazitschek R; Van Duzer JH; Jones S; Berton O
    Neuropsychopharmacology; 2014 Jan; 39(2):389-400. PubMed ID: 23954848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel class of anthraquinone-based HDAC6 inhibitors.
    Song Y; Lim J; Seo YH
    Eur J Med Chem; 2019 Feb; 164():263-272. PubMed ID: 30597327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent and selective inhibition of histone deacetylase 6 (HDAC6) does not require a surface-binding motif.
    Wagner FF; Olson DE; Gale JP; Kaya T; Weïwer M; Aidoud N; Thomas M; Davoine EL; Lemercier BC; Zhang YL; Holson EB
    J Med Chem; 2013 Feb; 56(4):1772-6. PubMed ID: 23368884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and SAR assessment of novel Tubathian analogs in the pursuit of potent and selective HDAC6 inhibitors.
    De Vreese R; Depetter Y; Verhaeghe T; Desmet T; Benoy V; Haeck W; Van Den Bosch L; D'hooghe M
    Org Biomol Chem; 2016 Feb; 14(8):2537-49. PubMed ID: 26822143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in the discovery of potent and selective HDAC6 inhibitors.
    Wang XX; Wan RZ; Liu ZP
    Eur J Med Chem; 2018 Jan; 143():1406-1418. PubMed ID: 29133060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
    Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF
    Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond the Selective Inhibition of Histone Deacetylase 6.
    Rodrigues DA; Thota S; Fraga CA
    Mini Rev Med Chem; 2016; 16(14):1175-84. PubMed ID: 27121714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors.
    Lin X; Chen W; Qiu Z; Guo L; Zhu W; Li W; Wang Z; Zhang W; Zhang Z; Rong Y; Zhang M; Yu L; Zhong S; Zhao R; Wu X; Wong JC; Tang G
    J Med Chem; 2015 Mar; 58(6):2809-20. PubMed ID: 25734520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity.
    Li S; Zhao C; Zhang G; Xu Q; Liu Q; Zhao W; James Chou C; Zhang Y
    Bioorg Chem; 2021 Nov; 116():105278. PubMed ID: 34474303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Rational Approach for the Identification of Non-Hydroxamate HDAC6-Selective Inhibitors.
    Goracci L; Deschamps N; Randazzo GM; Petit C; Dos Santos Passos C; Carrupt PA; Simões-Pires C; Nurisso A
    Sci Rep; 2016 Jul; 6():29086. PubMed ID: 27404291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.
    Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H
    Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.